O ver 1.4 million new cases of cancer are diagnosed each year in the United States, and it is expected that a subset of these patients will present with symptomatic metastatic lesions to the spinal column.
lieved to be technically more favorable in the treatment of tumors located in the thoracic spine, especially the mid-to upper thoracic spine, where the mediastinal contents make an anterior approach challenging.
There are a variety of posterior approaches for spinal metastases, including laminectomy with or without instrumentation for stabilization, transpedicular corpectomy, and costotransversectomy. Each approach is designed to address different clinical situations. A stand-alone laminectomy is generally considered only with metastatic involvement of the epidural space and lamina but is limited because it does not allow for decompression of ventral metastatic epidural spinal cord compression. Adding instrumentation for stabilization to a laminectomy can guard against instability due to tumor involvement of the facet joints, pedicles, or anterior vertebral body. The transpedicular corpectomy and costotransversectomy approaches provide the added benefit of ventrally decompressing the spinal cord or thecal sac and increasing the space between the lesion and the spinal cord for safer delivery of stereotactic radiosurgery (SRS). This is a significant advantage because the majority of spinal metastases occur ventrally in the vertebral body. 29 A costotransversectomy involves more extensive resection and bone removal, with concurrent improved access to the anterior spinal column from a more lateral trajectory.
The goal of this review is to critically evaluate each posterior approach, consider the clinical context for which each is intended, and make recommendations based on evidence for the role of each approach in the management of metastatic spine disease.
Methods search strategy
A review of the literature was performed using Medline and the bibliographies of the articles surveyed. The search query was broad and formulated to combine a number of subheadings and key words that included the interventions and pathology of interest. The search string employed was the following: "Spinal Neoplasms" [Mesh] 
Eligibility Criteria
Criteria for possible inclusion were as follows: articles published between 1980 and 2015; all articles in English or with an English translation; articles with 8 or more subjects; articles with adult age groups (18 years and older); articles describing the use of a posterior surgical approach; articles describing the treatment of metastatic spine disease; and fully published peer-reviewed studies including randomized controlled trials (RCTs), nonrandomized trials, cohort studies, and case control studies. Both prospective and retrospective studies were considered.
Criteria for exclusion were the following: articles describing intradural spinal tumors or combining intradural spinal tumors with metastatic spinal tumors, articles describing primary spinal tumors or combining primary spinal tumors with metastatic spinal tumors, articles with pediatric age groups, articles reporting only surgical treatment of metastatic spine disease without noting clinical outcomes, articles describing only an anterior approach, articles with no extractable data specific to metastatic spine morbidity, and case reports.
results

Posterior laminectomy with and without instrumentation
Of the 34 articles selected for this review, 17 featured the use of a PL ( Table 1) . Authors of these papers reported neurological, survival, recurrence, pain, and complication outcomes. There was 1 RCT, 37 2 prospective cohort trials, 14, 22 and 14 retrospective case series. 2, 3, 6, 7, 15, 17, 19, 23, [25] [26] [27] [28] 31 As regards neurological outcomes for laminectomy alone without instrumentation for stabilization, Class II data are provided by Young et al. 37 In their RCT of 29 patients, laminectomy followed by radiotherapy (RT) was compared with RT alone for the treatment of spinal metastases. Inclusion criteria were a neurological symptom, myelographic extradural block, and tissue diagnosis of metastasis. Among the patients treated with laminectomy and RT, 3 (50%) of 6 patients who were ambulatory before treatment remained ambulatory immediately after treatment and 4 (44%) of 9 patients not ambulatory before treatment regained ambulation. One patient was paraplegic and did not become ambulatory. There was no significant difference in neurological outcomes when comparing laminectomy plus RT to RT alone. Pain alleviation was noted in 6 (43%) of the 14 patients who had initially reported pain as a symptom and were treated with laminectomy and RT.
The study by Young et al. 37 was an RCT but was considered Class II data for our analysis. Our biggest concern was the small sample size, which impaired the strength of any conclusions that could be reached from the data. Only 16 patients were treated with laminectomy and RT. When this cohort of patients was further divided into ambulatory and nonambulatory groups for statistical analysis, the sample sizes were less than 10 per group. With such small sample sizes, the power of the study was limited. Another concern about this study was the inclusion of 5 patients with lymphoma, which is typically not treated with surgical intervention now. Finally, the authors did not mention how many patients were evaluated for inclusion but not enrolled in the study, whether there was any crossover between treatment groups, or whether any patients were lost to follow-up.
The study by Patchell et al. 24 also compared surgery in combination with RT to RT alone but had results pro- foundly different from those of Young et al. 37 However, Patchell and colleagues did not provide any outcome data specific to surgical approaches; therefore, their study was not useful for our analysis of specific surgical approaches.
Class II evidence was available from 2 prospective studies of laminectomy with instrumentation. Fuentes et al.
14 evaluated outcomes in 14 patients with vertebral metastatic lesions who underwent a posterior approach decompressive laminectomy followed by posterior instrumentation-assisted stabilization and open kyphoplasty. These authors reported the percentage of patients with improved or maintained (I/M) Frankel grades (100%). 14 Mühlbauer et al. 22 (17 patients) evaluated circumferential decompression through a single-stage posterior midline approach laminectomy with spinal reconstruction. 22 The reported neurological outcomes were overall percentage of patients with neurological improvement (82%) and percentage of nonambulatory patients at presentation who walked postoperatively (NAWPO; 70%). 22 Class III evidence was available from the 14 remaining retrospective studies selected, all case series except for a matched-pair analysis. Five of these 14 retrospective series used a PL only, without stabilization instrumentation. Bach et al. 3 (398 patients) evaluated different treatments to reduce metastatic spinal cord compression (MSCC). They divided the patients into treatment groups: PL, RT, or PL followed by RT (PL+RT). 3 The percentage of patients who experienced neurological improvement was as follows: PL = 44%, RT = 35%, PL+RT = 59%. 3 In a follow-up study, Bach et al. evaluated outcomes in patients experiencing MSCC due to lung carcinoma and found similar data when comparing the efficacy of PL with that of RT (PL = 48%, RT = 46%, PL+RT = 67%). 2 Chaichana et al. 6 (78 patients) evaluated the use of PL on metastatic epidural spinal cord compression based on tumor location and the patient's circumstances. 6 Of the 55 patients who were able to ambulate preoperatively, 24 (44%) underwent a PL. Twenty-three patients were unable to ambulate preoperatively, and 19 (83%) underwent a PL. The remaining patients underwent other approaches. Chaichana et al. did not specifically indicate outcomes for the patents who had the PL; however, they did report overall postoperative ambulatory outcomes for the patients who could walk preoperatively (patients who could walk postoperatively [WPO]: 78%) and for those who were nonambulatory preoperatively (NAWPO: 52%). 6 In the study by North et al.
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(61 patients), 24 patients underwent laminectomy with a posterior approach and 13 underwent laminectomy with fusion or placement of instrumentation. The authors did not specifically report the surgical outcomes but they did report the WPO as 96.7% and the WPO at 6 months as 81%. They also stratified ambulatory status according to cancer type and reported significantly longer retention of ambulation among patients afflicted with breast cancer (p = 0.013). The study by Rades et al. 26 also compared surgery in combination with RT to RT alone for "unfavorable" tumors (non-small cell lung cancer, cancer of unknown primary origin, renal cell cancer, and colorectal cancer). Their results were also different from those of Patchell et al., and they concluded that PL with RT was no different from RT alone in terms of ambulatory status following treatment, local control, or survival at 6 and 12 months. 24 Twenty-four patients underwent laminectomy and RT in this matched-pair analysis.
Seven of the retrospective case series reported on the use of PL with stabilization. Rompe et al. 27 (106 patients) evaluated the outcome of PL plus subsequent stabilization with Cotrel-Dubousset instrumentation. The number of patients who underwent PL was not reported; however, the authors noted that the most common operative treatment was PL and resection of the facet joints, including the removal of osseous or tumorous masses. Overall neurological outcomes were reported: neurological improvement, 62.5%; I/M Frankel grades, 95%; and WPO after 1 year, 79%. 27 In the study by Hirabayashi et al. 15 (81 patients), 24 patients underwent palliative surgery that included tumor resection and decompression of the spinal cord together with PL with or without instrumentation. They reported an overall WPO of 70%; however, they also stratified ambulatory status based on cancer type and reported the longest ambulation time for patients with myeloma (median 44.1 months). The remaining median ambulation times were as follows: prostate carcinoma (22.6 months), thyroid carcinoma (21.4 months), lung carcinoma (14.0 months), and liver carcinoma (7.9 months). Hirabayashi et al. also noted that patients who had "favorable" primary tumors (for example, prostate, bone marrow, thyroid) had longer median ambulation times (22.4 months) than those with "unfavorable" tumors such as lung, liver, breast, rectal, kidney, gastrointestinal, and pancreatic cancers (6.9 months; p < 0.0001). In the study by Jansson and Bauer 17 (282 patients), a group of 212 patients with neurological deficits due to thoracic or lumbar spinal metastases were evaluated after undergoing posterior decompressive laminectomy with stabilization; the remaining patients were managed with various other approaches. The authors did not specifically report neurological outcomes for the posterior approach, although the overall neurological outcome in terms of I/M Frankel grades was 95%. Chen et al.
7 (70 patients) described the use of palliative surgery via PL and subsequent stabilization with instrumentation for MSCC. The measured outcomes were patients with neurological improvement (70.4%) and increased activity in bedridden patients (60%). Placantonakis et al. 25 (90 patients) evaluated the outcomes of 70 patients with metastatic spine disease who had undergone posterolateral laminectomy including uni-or bilateral facetectomy and posterior instrumentation following resection of cervicothoracic junction tumors. The percentage of patients who had improved American Spinal Injury Association (ASIA) grades was 32%. Shimizu et al.
31 (11 patients) reported on the use of PL with stabilization for multiple metastatic tumors of the spine. The reported outcomes were neurological improvement (82%) and neurological deterioration (0%). Yang et al. (217 patients) analyzed the prognostic factors associated with survival time after a spinal metastasis operation and found that patients who underwent decompressive laminectomy without instrumentation had a median survival of 5.0 months, whereas those who underwent decompressive laminectomy with instrumentation had a median survival of 9.0 months, and the difference between the two was not significant. 36 These authors also analyzed anterior corpectomy and did not stratify survival, complications, functional status, or other factors by tumor type or operation.
Two of the retrospective case series used a posterior approach with intraoperative RT. Kondo et al. 19 (96 patients) evaluated the use of intraoperative RT combined with a PL and stabilization in patients with nonambulatory paralysis due to metastatic spine disease. The reported outcomes were WPO (88%) and I/M Frankel grades (89%). 19 Saito et al. 28 (79 patients) evaluated the outcomes of PL and resection of an epidural metastatic tumor with intraoperative RT for the treatment of spinal metastasis. The reported outcomes were improvement by at least one Frankel grade (86%) and NAWPO (78%). 28 Thirteen of the 17 studies addressing the use of PL reported survival data. Young et al. reported a mean survival of 27.5 weeks for patients who underwent laminectomy. 37 Of the 2 prospective studies on PL, only the one by Mühl bauer et al. reported a median survival outcome, which was 10 months. 22 Twelve of the 13 retrospective case series reported survival outcomes. Bach et al. 3 found that survival was best for patients treated with both PL and RT, reporting median survival times of 2.8 months following PL, 2.3 months following RT, and 5.4 months following PL+RT. In a follow-up study, these same authors 2 evaluated outcomes for lung carcinoma and revealed similar results, showing median survival times of 1.5 months after PL, 1 month after RT, and 3.5 months after PL+RT. The remaining studies reported overall median survival time (17 months, 19 10 months, 25 ), or overall survival of patients at the 3-month follow-up (87%, 7 63% 17 ). North et al. reported an overall median survival of 10 months and also stratified survival based on tumor pathology, documenting a median survival of 1.7 years in breast cancer patients (HR 0.348, p = 0.02) and 3 months in lung cancer patients. 23 Although Hirabayashi et al. documented an overall median survival of 10.6 months, they also stratified survival outcomes according to tumor pathology and reported that myeloma (44.4 months), thyroid carcinoma (25.5 months), prostate carcinoma (20.1 months), breast carcinoma (18.6 months), rectal carcinoma (15.2 months), primary tumor in the pancreas (5.7 months), esophagus (4.7 months), and stomach (2.1 months) had shorter median survivals. Patients with myeloma, thyroid carcinoma, or prostate carcinoma had significantly longer survival than patients with primary tumors in the esophagus, liver, lung, or pancreas (p < 0.05). 15 Univariate analysis showed that the anatomical site of the primary tumor, postoperative ambulation, and combined adjuvant therapy (chemotherapy plus RT) were associated with prolonged survival (p < 0.05). Multivariate analysis revealed that the primary tumor site and postoperative ambulatory function were independent predic-tors of prolonged survival (p < 0.0001). There were also significant correlations between ambulation time and survival time in patients who were able to walk postsurgery (p < 0.0001), even in patients with liver (p < 0.05) or lung carcinoma (p < 0.05).
With respect to recurrence outcomes, 8 of the 17 publications reported data for patients' recurrence rates (RRs): 21%, 15 18%, 31 8.5%, 7 6%, 17,19 5.6%, 27 2.5%. 28 Rades et al. 26 reported a local control rate of 93% at 6 months and 85% at 12 months. As regards pain alleviation outcomes, 10 of the 17 papers reported relevant data. The RCT by Young et al. 37 did not directly measure pain reduction; however, the investigators did note that patients in the surgery plus RT group had reduced use (38% improvement) of narcotic analgesics. Of the 2 prospective studies, only one reported a pain outcome, indicating that 100% of the patients had reduced scores on the visual analog scale (VAS) for pain. In all 17 publications, a PL was used based on the location of the tumor and the surgeon's familiarity with the approach and reconstructive options. 2,3,6,7,14,15,17,19, 22,23, 25-28, 31, 36,37 Posterior approach laminectomy with instrumentation was used to stabilize the spine in 11 studies. 7, 14, 15, 17, 19, 22, 24, 25, 27, 31 A PL was used with intraoperative RT to treat residual spinal metastatic tumor in 2 studies due to the severity of the spinal metastases. 19, 28 
transpedicular Corpectomy
Of the 34 publications selected for this review, 14 documented the use of the posterolateral transpedicular approach (PTA; Table 2 ). Of note, Laufer et al. analyzed local tumor control using the same data set as Wang et al. 20, 33 These papers provided results for neurological outcomes, survival, recurrence, pain, and complication rates. There were 3 prospective cohort trials 32, 33, 38 and 11 retrospective case series. 4, 5, [8] [9] [10] 12, 13, 18, 20, 30, 34 Class I evidence reporting on the use of PTAs was not available from any of the selected articles.
As regards neurological outcomes, Class II evidence was available and provided by 3 prospective studies by Street et al., 32 Wang et al., 33 and Zairi et al. 38 The study by Street et al. (42 patients) sought to evaluate single-stage posterolateral vertebrectomy for disease of the lumbar spine or combined bilateral costotransversectomies in the thoracic spine. 32 The neurological outcome reported was neurological improvement (100%). Wang et al. (140 patients) investigated the use of single-stage PTA with instrumentation for the resection of epidural metastatic spine tumors involving the vertebral body with circumferential reconstruction. 33 They reported the neurological outcomes of neurological improvement (90%), NAWPO (75%), and I/M ASIA grades postoperatively (96%). Zairi et al. (10 patients) performed a prospective evaluation of minimally invasive transpedicular vertebrectomy and spinal cord decompression and stabilization using a tubular expandable retractor for the palliative management of symptomatic thoracolumbar spine metastasis. 38 These authors reported no intraoperative complications and one patient with a urinary tract infection postoperatively. Eight patients (80%) improved at least 1 Frankel grade, and all patients had pain improvement. The mean follow-up was 10.1 months, and 40% of the patients died within that period of time. The authors concluded that minimally invasive treatment of thoracolumbar metastasis was safe and effective in patients with limited life expectancy.
Class III evidence was provided by the 11 remaining retrospective case series reporting on PTAs. Bilsky et al. 18 (8 patients) evaluated single-stage PTA for circumferential epidural decompression and 3-column stabilization using a titanium cage for upper thoracic spine neoplastic disease and reported one neurological outcome (I/M Frankel grades 100%). Senel et al. 30 (7 patients) evaluated circumferential stabilization with ghost screwing (that is, the creation of an acrylic anterior graft that is directly connected to the posterior transpedicular stabilizing system via 2 ghost screws) after posterior resection of spinal metastases via a transpedicular route. They reported that neurological function remained unchanged for all patients not lost to follow-up. Weller and Rossitch 34 (8 patients) evaluated unilateral posterolateral decompression without stabilization for neurological palliation of symptomatic spinal metastasis in debilitated patients. All patients with preoperative motor deficits demonstrated increased motor strength postoperatively, and all were able to ambulate either independently or with the assistance of a cane; thus, neurological improvement was 100%. Cahill and Kumar 5 (9 patients) specifically used a single midline posterior approach to perform single-stage circumferential decompression of the cord followed by anterior and posterior reconstruction; they reported one neurological outcome (WPO: 88%). Lastly, Eleraky et al.
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(8 patients) used a posterior transpedicular corpectomy for malignant cervical spine tumors in 7 patients and reported that all 7 improved or maintained their Frankel grade of function (100%).
None of these studies stratified survival based on tumor pathology. Two of the prospective studies reported outcomes: Street et al. noted that 75% of patients were alive at 6 months, 32 and Wang et al. noted an overall median survival of 7.7 months. 33 Seven of the 11 retrospective studies reported survival outcomes as overall median survival time (11.3 months, 9 9.75 months, 4 8.9 months, 10 8.8 months 8 ), survival at the 12-month follow-up (43%, 30 37.5% 12 ), and survival at 6 months (88.9%). 5 Only 9 of the 14 studies reported RRs. Two of the prospective studies reported RRs of 11% 33 and 2.4%. 32 Seven of the retrospective studies reported RRs of 14%, 10 11.1%, 5 8%, 4 4.3%, 9 3.2%, 8 and 0%. 12, 18 Pain palliation outcomes were reported in 11 of the 14 studies. In all 3 prospective studies, the outcome measured was pain relief (100% 32,38 and 96% 33 ). Eight of the 11 retrospective studies reported pain relief (100%, 4, 5, 13, 30, 34 95.2%, 10 88%, 18 and 62.5%
12
). Laufer et al. 20 described the clinical outcomes and local tumor control for spinal metastases following "separation surgery" and SRS. These authors found that the incidence of local progression was 16.4% at 1 year after SRS and was improved with highdose hypofractionated SRS (4.1% cumulative incidence of local progression at 1 year, HR 0.12, p = 0.04) as opposed to low-dose hypofractionated SRS (22.6% local progression at 1 year, HR 1). The median follow-up was 7.6 months (range 1.0-66.4 months). 20, 21 The pain, functional, and neurological results of posterolateral decompression and stabilization had been analyzed and reported in an earlier publication.
Complication outcomes were reported in 10 of the 14 studies. In 2 of the prospective studies, SCs were reported (26%, 32 14.3% 33 ). Wang et al. 33 also described a median blood loss of 1500 ml and wound infection rate of 11.4%. Eight of the 11 retrospective studies reported complication outcomes such as SCs (30.4%, 8 ). Authors in all 14 studies reported performing a PTA based on the location of the tumor and the surgeon's familiarity with the approach and reconstructive options. 4, 5, [8] [9] [10] 12, 13, 18, 20, 30, [32] [33] [34] 38 A posterior transpedicular approach with instrumentation was used in 7 studies to stabilize the spine. 4, 5, 10, 18, 20, 30, 33 Deutsch et al. reported that a PTA was also used over an anterior approach owing to age, comorbidities, and limited life expectancies.
Costotransversectomy
Of the 34 publications selected for this review, 4 used a posterolateral costotransversectomy approach (PCT; Table 3). These papers provided results on neurological outcomes, survival, recurrence, pain, and complication rates. There was 1 prospective cohort trial, 32 1 retrospective case-control study, 35 and 2 retrospective case series. 11, 23 Class I evidence on the use of PCT was not available from any of the selected articles.
As regards neurological outcomes, Class II evidence was available and provided by the prospective study by Street et al. 32 As previously mentioned, Street et al. (42 patients) evaluated single-stage posterolateral vertebrectomy for disease of the lumbar spine or combined bilateral costotransversectomies in the thoracic spine. Their study was selected as evidence supporting both PTA and PCT because they used a combined approach and because of the limited available literature on PCT approaches for metastatic spine disease. The neurological outcome reported was neurological improvement (100%). Class III evidence was provided by the 3 retrospective studies. In a retrospective comparison study, Wiggins et al. 35 evaluated outcomes after performing 29 PCTs (Group 1) and 18 thoracolumbar or combined approaches (Group 2) as initial operations for thoracic neoplasms. The outcomes reported were mean Frankel grade at discharge (4.1 vs 4.7, respectively, p = 0.74) and mean ASIA motor score at discharge (90.4 [range 50-100] vs 98.3 [range 75-100], respectively, p = 0.04). Both of the retrospective case series addressing PCT reported neurological outcomes. In the study by North et al. 23 (61 patients), 3 patients underwent a PCT. Although this study is repeated in this review, we decided to include it given the limited available literature on PCT. The outcome of the surgical management for the PCT subgroup of patients was not reported; however, North et al. did report overall neurological outcomes for WPO (96.7%) and the WPO at 6 months (81%). These authors also stratified ambulatory status based on cancer type and reported that ambulatory status endured the longest in breast cancer patients (p = 0.013). 23 Cybulski et al.
11 (15 patients) conducted spinal cord decompression via modified PCT approach combined with posterior instrumentation for management of metastatic neoplasms of the thoracic spine. The neurological outcome reported was WPO (80%).
11
As regards survival outcomes, 3 of the 4 studies reported data. In the prospective study, 75% of the patients were alive at the 6-month follow-up and 50% survived for more than 12 months postoperatively. 32 The 2 retrospective case series also reported survival outcomes. Cybulski et al. reported that 53% lived longer than 12 months, 11 and North et al. noted an overall median survival of 10 months. 23 However, North and colleagues also stratified survival based on tumor pathology and reported that the median survival ranged from 1.7 years in patients with breast cancer to 3 months in lung cancer patients. 23 As regards the RR, only 1 of the 4 studies reported this outcome; Street et al. reported the only case of recurrence, in which 1 patient had a gastrointestinal adenocarcinoma who had received preoperative RT. 32 As for pain palliation outcomes, 3 of the 4 papers reported data. In the prospective study, all patients had a statistically significant decrease in the subjective reporting of pain. 32 The mean preoperative VAS score was 9.94 and reduced to 4.3 postoperatively. The 2 retrospective case series reported pain relief in 56% 23 and 73% 11 of treated patients. Surgical complication rates were reported by all 4 studies. The prospective study reported 26%. 32 The retrospective case-control study reported 38% for Group 1 versus 39% for Group 2 (p = 0.95). 35 The 2 retrospective case series reported 8.1% 23 and 7%.
The PCT approach was used in these studies because of tumor location, 11, 23, 32, 35 severity of disease, patient health, 11, 23, 32, 35 surgeon's familiarity with the approach and reconstructive options, 11, 23, 32, 35 and patient comorbidities. 11, 32, 35 In Wiggins et al., PCT was selected if the tumor extended into the posterior elements or paraspinal musculature. 35 However, a thoracolumbar or combined approach was selected if the tumor had direct extension anterior to the spine or through the pleura. Posterolateral costotransversectomy was also elected if a patient had multiple levels of disease or noncontiguous disease, if the surgeon believed that anterior stabilization was not going to restore spinal stability after tumor resection, if patients had significant medical comorbidities, or if patients could not tolerate a thoracotomy. 35 
summary and Discussion
Posterior laminectomy with and without instrumentation
Among the studies investigating PL either with or without instrumentation, Class II evidence was available from the RCT by Young et al. 37 and 2 prospective case series conducted by Fuentes et al.
14 and Mühlbauer et al. 22 Class III evidence was available from 13 retrospective case series.
Neurological Improvement and Pain Palliation
Class II data were provided by Young et al. 37 for laminectomy plus RT versus RT alone with regard to neurological improvement (Table 4 ). In short, laminectomy added to RT provided no additional benefit compared with RT alone for either neurological status or pain. Class II evidence on neurological improvement and pain palliation for laminectomy with instrumentation was provided by both prospective case series reported by Fuentes et al. 14 and Mühlbauer et al. 22 Both studies reported neurological improvement; however, only Fuentes et al. reported on pain palliation. In addition, all 14 retrospective case series addressing posterior surgical intervention reported some form of neurological outcome. Among these 14 studies, the most common neurological outcome reported was neurological improvement. In some studies patients showed improvement in Frankel, ASIA, or Nurick grades, which also counted as neurological improvement. Overall, in the retrospective case series, neurological improvement ranged from 22% to 95%, with a median of 71.75% (Fig.  1) . The second most common neurological outcome was WPO, which ranged from 70% to 97% with a median of 83.5% (Fig. 2) . The third most common neurological outcome was NAWPO, which ranged from 52% to 78% with a median of 71.1%. Hirabayashi et al. was the only study to stratify neurological outcome in terms of LWPO based on cancer type: myeloma (median 44.1 months), prostate carcinoma (22.6 months), thyroid carcinoma (21.4 months), lung carcinoma (14.0 months), and liver carcinoma (7.9 months). 15 These authors also reported that patients with "favorable" primary tumors had a longer median ambulation time (22.4 months) than those with "unfavorable" tumors (6.9 months; p < 0.0001). 15 Only 8 of the retrospective case series reported outcomes addressing pain palliation, and the most common was the percent of patients that experienced pain relief, which ranged from 56% to 100% with a median of 77.65% (Fig. 3) .
Survival Outcomes and Rates of Recurrence and Complications
Young et al. 37 noted a mean survival of 27.5 weeks following laminectomy plus RT compared with 23.4 weeks after RT alone (Table 4) . However, no statistical analysis was provided; therefore, no conclusions could be reached with these data. Class II evidence of survival outcomes was provided by the prospective case series by Mühlbauer et al., 22 who reported a mean survival of 10 months. These 2 prospective studies had 0% reported surgical complications. In addition, 12 of the retrospective case series addressing the posterior approach surgical intervention reported survival outcomes, most often as the median survival time, which ranged from 1.5 to 17 months with a median of 10.3 months (Fig. 4) . The next most common outcome was mean survival time, which ranged from 10.4 to 19.2 months with a median of 14.8 months. Survival was stratified by tumor pathology in 2 studies. North et al. 23 reported that the overall median survival was 10 months, and after stratifying for survival based on tumor pathology, they reported a median survival of 1.7 years in breast cancer patients and 3 months in lung cancer patients. Although Hirabayashi et al. reported that the overall median survival for patients postoperation 15 This was consistent with the idea that patient survival is intimately correlated to the origin of the primary tumor. Eight of the retrospective case series reported recurrence outcomes, and the most common was the RR in patients, which ranged from 2.5% to 21% with a median of 6% (Fig. 5) . None of the studies reported the RR stratified by tumor pathology. Only 9 of the retrospective case series reported complication outcomes, most commonly the percentage of patients that experienced SCs, which ranged from 0 to 25% with a median of 13.5% (Fig. 6 ). In summary, Class II data from Young et al. 37 suggested that laminectomy without instrumentation did not provide any significant benefit when combined with RT compared with RT alone. However, other Class II data from prospective cohorts demonstrated that laminectomy combined with instrumentation for stabilization could improve neurological outcomes 14, 22 and pain. 14 However, these prospective studies did not have control groups, so again conclusions were limited. Interestingly, one of the retrospective studies stratified neurological improvement according to tumor pathology and found plasmacytomas and hepatocellular carcinomas to be associated with the best and worst neurological prognosis (as indicated by ambulation time after surgery), respectively. 15 With respect to survival, a total of 14 studies reported survival outcomes that varied significantly. A multicenter prospective study conducted by Ibrahim et al. 16 demonstrated that patients undergoing tumor excision had better survival outcomes than those receiving only palliative therapy. One of the studies stratified survival outcomes based on tumor origin and found that plasmacytomas and stomach cancers were associated with the best and worst prognostic survival outcomes, respectively. 15 Complication outcomes varied significantly among the different studies, with some authors reporting a complete absence of complications and some reporting a 25% complication rate. It is possible that this wide range of complication outcomes is associated with the primary tumor pathology, the level approached, and patient comorbidities. All of these factors were not formally assessed in the literature but should be accounted for in future studies that address complications. This is emphasized in the study by Chaichana et al., who stated that nonambulatory patients had an increased rate of postoperative complications. The RRs were also highly variable and difficult to interpret and compare since they were stratified by neither tumor pathology nor the extent of resection (for example, en bloc or excisional). Given the lack of high-level evidence and adequately powered studies, the magnitude of all outcomes assessed in this review could not be confidently quantified. Thus, all conclusions drawn from the provided data should be carefully integrated with clinical experience and the individual patient when selecting a PL with or without instrumentation for surgical intervention.
transpedicular Corpectomy
Among the studies investigating transpedicular corpectomy, Class I evidence was unavailable. Class II evidence supporting the use of PTA was limited to 3 studies by Street et al., 32 Wang et al., 33 and Zairi et al. 38 (Table  5 ). All 3 studies also reported a high percentage of patients who experienced pain palliation (100% 32,38 and 96% 33 ). In addition, all 11 retrospective case series addressing the use of a PTA reported some form of neurological outcome, most commonly neurological improvement. Some studies had patients show improvement in their Frankel, ASIA, or Nurick grades, which counted as neurological improvement. Overall, neurological improvement ranged from 33% to 100% with a median of 71.25% (Fig. 1) . The next most common neurological outcome reported was WPO, which ranged from 73.9% to 100% with a median of 81% (Fig. 2) . Only 8 of the retrospective case series reported pain palliation, most often the proportion of patients with pain relief, which ranged from 62.5% to 100% with a median of 100% (Fig. 3) .
Survival Outcomes and Rates of Recurrence and Complications
Class II evidence of survival outcomes was reported by the 3 prospective case series. Street et al. reported that 75% patients survived at 6 months and 50% survived at 12 months. 32 Wang et al. reported an overall median survival of 7.7 months. 33 Zairi et al. reported that 60% patients survived at 6 months. 38 However, none of the studies reported survival times stratified by tumor pathology. With respect to recurrence rates, 2 studies described low recurrence for PL compared with those for both PTA and PCT. This finding is in contrast to the notion that more aggressive circumferential approaches such as PTA and PCT yield better survival outcomes (Fig. 4) . Although the difference may appear clinically significant, it is uncertain whether it is statistically significant. Predictably, reported surgical complications were higher for PTA than for PL; however, those reported for PCT appeared to be much lower (Fig. 6 ). This is counterintuitive as one would expect the more invasive PCT approach to be associated with more frequent surgical complications. This discrepancy is most likely attributable to the scarcity of available outcomes literature on PCT approaches. Reported RRs were congruent with the clinical notion that circumferential decompression (PTA/PCT vs PL) results in more complete tumor resections and thus decreases recurrence. As regards the reported indications for choosing a posterior approach, the majority of authors used a particular posterior approach based on tumor location and the surgeon's familiarity with the approach and reconstructive options.
study limitations
While this study has sought to provide a comprehensive review of the posterior approaches for the treatment of spinal metastatic disease, note that the ability to draw comprehensive conclusions from the results provided in the reviewed studies was limited given the extensive variation in the scales used to report different outcomes. Moreover, a few of the included studies reported on a smaller number of patients, which suggests that the data may not be generalizable to all populations. Additionally, when possible, data from the studies were summarized for the most frequent outcome scales reported. Finally, some studies reported on more than one procedure; thus, data from these studies were used more than once. Even in light of these shortcomings, this review does provide essential information for clinicians.
Key issues for Future investigation
Determining the most appropriate surgical approach for an individual case depends on a number of factors, including tumor pathology, location, and general medical status of the patient. Multiple factors must be considered when determining the appropriate surgical management of MSCC since the presence of epidural metastasis alone does not require an instrumented reconstruction, although the optimal surgical approach should provide adequate exposure to safely remove the lesion. It is difficult to design a study that controls the important variables yet still has a large enough sample size to be of value. Therefore, future studies will be much more viable if they are multicenter trials to improve patient recruitment. There are weaknesses in the current body of literature that future studies will hopefully address. First, most currently available studies are retrospective. Even if randomized trials are difficult to execute, prospective data would be of value. Second, with few exceptions, the current available data represent case series and cohorts without comparison groups. Without a reasonable control group, any firm conclusions are not possible. Hopefully, future studies will provide data to 
